Wick Capital Partners’s Pfizer PFE Stock Holding History

Wick Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,036	Closed	-$364K	–	63
2022 Q1	$364K	Buy	7,036 +300	+4%	+$15.6K	0.24%	36
2021 Q4	$398K	Buy	+6,736	New	+$334K	0.31%	42

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wick Capital Partners's PFE Position: Q2 2022 in Review

Wick Capital Partners sold out of Pfizer (PFE) in Q2 2022, closing a stake of 7,036 shares — an estimated $364K sold.

Wick Capital Partners first reported a position in PFE in Q4 2021 and held it in 2 quarters. The position peaked at $398K in Q4 2021. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.

Wick Capital Partners reported no remaining Pfizer position as of Q2 2022 after selling out during the quarter.
Wick Capital Partners sold 7,036 Pfizer shares in Q2 2022, an estimated $364K.
Wick Capital Partners first reported a position in Pfizer in Q4 2021 and held it in 2 quarters.
Wick Capital Partners's Pfizer position peaked at $398K in Q4 2021.
3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.

Based on Wick Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.